drugset / Trial / NCT04800224

Brazilian Green Propolis Extract (EPP-AF) as an Adjunct Treatment for Hospitalized COVID-19 Patients (BeeCovid2)

NCT04800224

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) promotes challenging immune and inflammatory phenomena. Though various therapeutic possibilities have been tested against coronavirus disease 2019 (COVID-19), the most adequate treatment has not yet been established. Among candidate adjunct treatment options, propolis, produced by honey bees from bioactive plant exudates, has shown potential against viral targets and has demonstrated immunoregulatory properties.

Timeline

Start
2021-04-12
Primary completion
2021-07-30
Completion
2021-07-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator EPP-AF Unknown 900 mg Oral

Indications